Federal Judge Overturns $107.5 Million Verdict Against AstraZeneca in Pfizer Patent Case

A significant development occurred in the pharmaceutical patent litigation realm as a federal judge overturned a Delaware jury verdict, effectively freeing AstraZeneca from a $107.5 million liability. The case revolved around allegations that AstraZeneca had infringed on two cancer drug patents owned by a unit of Pfizer. The judge’s decision was based on the finding that both patents in question were invalid due to insufficient information about the invention. Legal professionals can delve deeper into the specifics of this ruling by accessing the [original article](https://www.law360.com/articles/1869954/astrazeneca-freed-from-107-5m-verdict-in-pfizer-patent-case) on Law360.